Esperion Therapeutics Inc. (NASDAQ: ESPR), a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers, today announced the Company will present at the Jefferies 2014 Global Healthcare Conference in New York City, N.Y. Tim M. Mayleben, president and chief executive officer, will provide an update on the company on Thursday, June 5 at 2:30 p.m. Eastern Time.
Help employers find you! Check out all the jobs and post your resume.
